Setmelanotide vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Imcivree, RM-493
Setmelanotide (brand name Imcivree) is a melanocortin-4 receptor (MC4R) agonist peptide and a genuine FDA-approved obesity drug, first cleared in 2020. It is not a general weight-loss shot like the GLP-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. It is given as a once-daily subcutaneous injection and has since been approved for additional conditions including Bardet-Biedl syndrome and acquired hypothalamic obesity.
Also: Semaglutide + Cagrilintide
CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.
Key Comparison Insights
- Setmelanotide is FDA approved, while CagriSema remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to CagriSema (Human Trials).
Detailed Comparison
| Attribute | Setmelanotide | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Deep in the hypothalamus there is a pathway that tells your brain you are full and that ramps up energy use. It runs through signals like leptin and POMC down to the MC4R receptor. In people with certain rare gene defects, such as POMC, PCSK1, or LEPR deficiency, that pathway is short-circuited upstream of MC4R, so the brain never gets the fullness signal and hunger is relentless. Setmelanotide bypasses the broken upstream step by binding and switching on MC4R directly, restoring the satiety and energy-expenditure signal. That is why it works specifically in these genetic and syndromic forms of obesity and would not be expected to fix common obesity the same way. | The combination works on two different appetite systems at once. Semaglutide mimics GLP-1, a gut hormone that boosts insulin after meals, slows stomach emptying, and signals fullness to the brain. Cagrilintide is a synthetic version of amylin, a hormone co-secreted with insulin from the pancreas, which reduces food intake and reinforces satiety through separate brain circuits in the hindbrain and hypothalamus. The idea, still being characterized, is that hitting GLP-1 and amylin pathways together produces more appetite suppression than either alone. Both components are engineered for slow release so a single weekly dose maintains steady drug levels. |
| Common Dosing | 2-3 mg daily Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection daily | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The human evidence is strong but deliberately narrow, matching the rare diseases it treats. The pivotal single-arm, open-label phase 3 trials in POMC and LEPR deficiency, published in The Lancet Diabetes and Endocrinology in 2020, reported that 80 percent of POMC patients and 45 percent of LEPR patients achieved at least 10 percent weight loss at about one year, alongside large drops in hunger scores. A separate randomized, placebo-controlled phase 3 trial supported approval in Bardet-Biedl syndrome, and a 2024 open-label trial (VENTURE) extended evidence to children as young as two. The trials were small because these conditions are extremely rare, so the data are best read as convincing within those specific genetic populations rather than as evidence for obesity broadly. The common side effects are consistent and manageable: skin hyperpigmentation, injection-site reactions, nausea, and headache, with no serious treatment-related events reported in the core trials. This is a legitimate approved drug for defined genetic indications, not an off-label general weight-loss peptide. | This is one of the better-tested experimental obesity drugs because it went straight into large human phase 3 trials rather than living only in animal data. In REDEFINE 1, about 3,400 adults with overweight or obesity but without diabetes were randomized over 68 weeks; CagriSema produced roughly 20.4% average body weight loss versus 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3.0% for placebo, with results published in the New England Journal of Medicine in 2025. REDEFINE 2 tested it in adults with type 2 diabetes and also met its endpoints, showing meaningful weight loss and HbA1c improvement compared with placebo. Notably, the headline 20% figure landed below Novo Nordisk's own 25% target, which disappointed investors even though the drug clearly worked. The most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the GLP-1 plus amylin class. CagriSema is not FDA-approved as of mid-2026, so anything sold under that name outside a clinical setting is unregulated. |
Frequently Asked Questions: Setmelanotide vs CagriSema
What is the difference between Setmelanotide and CagriSema?
Setmelanotide is a weight loss peptide that setmelanotide (brand name imcivree) is a melanocortin-4 receptor (mc4r) agonist peptide and a genuine fda-approved obesity drug, first cleared in 2020. it is not a general weight-loss shot like the glp-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. it is given as a once-daily subcutaneous injection and has since been approved for additional conditions including bardet-biedl syndrome and acquired hypothalamic obesity. CagriSema is a weight loss peptide that cagrisema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a glp-1 receptor agonist, the molecule behind ozempic and wegovy) and cagrilintide (a long-acting amylin analog). it is being developed by novo nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 redefine trials. it is not yet approved by the fda, though regulatory filings are underway. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Setmelanotide or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. Setmelanotide is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Setmelanotide and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Setmelanotide and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.